A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors.

Published in:

Investigational New Drugs, 2020, v. 38, n. 1, p. 120, doi. 10.1007/s10637-019-00754-y

By:

• Rosen, Lee S.;
• Wesolowski, Robert;
• Baffa, Raffaele;
• Liao, Kai-Hsin;
• Hua, Steven Y.;
• Gibson, Brenda L.;
• Pirie-Shepherd, Steven;
• Tolcher, Anthony W.

Publication type:

Article